



(11)

**EP 1 991 263 B8**

(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:  
**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 84**

(51) Int Cl.:  
**A61K 39/02 (2006.01) C12N 15/74 (2006.01)**

(86) International application number:  
**PCT/US2007/005457**

(48) Corrigendum issued on:  
**25.02.2015 Bulletin 2015/09**

(87) International publication number:  
**WO 2007/103225 (13.09.2007 Gazette 2007/37)**

(45) Date of publication and mention  
of the grant of the patent:  
**24.12.2014 Bulletin 2014/52**

(21) Application number: **07752174.8**

(22) Date of filing: **01.03.2007**

(54) **ENGINEERED LISTERIA AND METHODS OF USE THEREOF**

MANIPULIERTE LISTERIEN UND ANWENDUNGSVERFAHREN DAFÜR

LISTÉRIA GÉNÉTIQUEMENT MODIFIÉE ET PROCÉDÉS POUR SON UTILISATION

(84) Designated Contracting States:  
**AT BE BG CH CY CZ DE DK EE ES FI FR GR HU**  
**IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI**  
**SK TR**

(30) Priority: **01.03.2006 US 778471 P**  
**21.03.2006 US 784576 P**  
**30.03.2006 US 396216**  
**30.03.2006 US 395197**

(43) Date of publication of application:  
**19.11.2008 Bulletin 2008/47**

(60) Divisional application:  
**14193181.6**

(73) Proprietor: **Aduro Biotech**  
**Berkeley, California 94710-2225 (US)**

(72) Inventors:  
• **DUBENSKY, Thomas, W., Jr.**  
**Piedmont, CA 94611 (US)**  
• **SKOBLE, Justin**  
**Berkeley, CA 94703 (US)**  
• **LAUER, Peter, M.**  
**Albany, CA 94706 (US)**

• **COOK, David, N.**  
**Lafayette, CA 94549 (US)**

(74) Representative: **Brasnett, Adrian Hugh et al**  
**Mewburn Ellis LLP**  
**33 Gutter Lane**  
**London EC2V 8AS (GB)**

(56) References cited:  
**WO-A-2004/110481 WO-A-2005/071088**

• **BROCKSTEDT DIRK G ET AL: "Recombinant**  
**listeria monocytogenes-based immunotherapy**  
**targeting mesothelin for the treatment of**  
**pancreatic and ovarian cancer." PROCEEDINGS**  
**OF THE AMERICAN ASSOCIATION FOR CANCER**  
**RESEARCH ANNUAL MEETING, vol. 46, April**  
**2005 (2005-04), page 1418, XP001536813 & 96TH**  
**ANNUAL MEETING OF THE AMERICAN-**  
**ASSOCIATION-FOR-CANCER-RESEARCH;**  
**ANAHEIM, CA, USA; APRIL 16 -20, 2005 ISSN:**  
**0197-016X**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**EP 1 991 263 B8**

- **BROCKSTEDT D G ET AL: "Listeria-based cancer vaccines that segregate immunogenicity from toxicity" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE, WASHINGTON, DC, US, vol. 101, no. 38, 21 September 2004 (2004-09-21), pages 13832-13837, XP002305523 ISSN: 0027-8424**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification